Wayne G. Brisbane

Wayne G. Brisbane, MD, is an Assistant Professor in the Department of Urology at the University of California, Los Angeles (UCLA), specializing in Urologic Oncology with a primary focus on prostate cancer diagnostics and treatment. He practices clinically at Westwood Urology in Los Angeles and maintains hospital affiliations across UCLA Health's major facilities including Ronald Reagan UCLA Medical Center and UCLA Santa Monica Medical Center.

His educational background includes:

• MD from Loma Linda University School of Medicine (2013)
• BA from Seattle Pacific University (2008)
• Urology Residency at the University of Washington School of Medicine (2019)
• General Surgery Internship at the University of Washington School of Medicine (2014)
• Urologic Oncology Fellowship at UCLA (2021)

Dr. Brisbane's research centers on optimizing prostate cancer imaging for risk stratification and treatment guidance, with particular expertise in Micro-Ultrasound, MRI, and PSMA PET technologies. His clinical work emphasizes image-guided biopsy, robotic prostate surgery, and focal therapy techniques designed to maximize cancer cure rates while minimizing treatment side effects through personalized patient care.

Analysis of his recent publications reveals a consistent research trajectory advancing prostate cancer diagnostics through multimodal imaging integration. Key themes include developing precision biopsy protocols, creating risk assessment tools combining clinical and imaging data, and refining minimally invasive ablation methods for targeted cancer treatment.

His scientific recognition includes:

• Prostate Cancer Foundation - Young Investigator Award

As an active clinician-researcher, Dr. Brisbane participates in multiple prostate cancer clinical trials including the Micro-US Registry and MMUVE Prostate Cancer study, though specific grant funding and mentoring activities aren't detailed in available materials.

He collaborates within UCLA's Cancer Molecular Imaging, Nanotechnology and Theranostics group and contributes to AI-driven prostate cancer research initiatives, recently highlighted in UCLA Health's 2025 coverage of innovations in prostate cancer care and artificial intelligence applications.